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OBJECTIVES:Multiple medical reimbursement systems exist in Europe, which may
create unequal dissemination and coverage of innovative medical devices. Even in
the setting of regularly revised systems, uptake of new technology may be delayed
leading to unequal reimbursement. METHODS: This study analyzed the 2010 geo-
graphical trends of transcatheter aortic valve implantation (TAVI) rates in 14 coun-
tries (Medtronic CoreValve System and Edwards Sapien). Implant data were gath-
ered from BIBA Medical Ltd, a UK-based provider of consulting and market analysis
services for the medical device industry. In addition demographic and economic
data were gathered from Eurostat, a statistical office of the European Union. Re-
gression techniques were used to explore the relationship between implant rate
and a number of key variables. RESULTS: In 2010, a total of 14,400 TAVI procedures
were documented providing an average country-based implant rate of 36.2 per
million/Inhabitants. A seven-fold difference in implantation rate existed between
the highest and lowest implanting countries (Germany, 77 per million/inhabitants
vs. Norway 12 per million/inhabitants). Implant rates were correlated with per-
capita GDP (r20,015), health expenditure (r20.15) and number of implanting cen-
ters in the country (r20.18). At this time, only two European countries have a
dedicated tariff for TAVI that is applicable nationwide and covers both the device
and the procedure (Germany – €34,900, France - €28,477). Differences between
country-specific tariffs depend on the method of DRG calculation. In Austria, the
TAVI tariff was made to equal that of surgical aortic valve replacement. Countries
such the UK and Italy have adopted case-by-case funding. In countries such as
Belgium and the The Netherlands TAVI is funded by the hospital-based budget.
CONCLUSIONS: Significant differences in TAVI rates exist among European coun-
tries. These observations may help us to better understand unequal patterns of
dissemination and coverage of innovative medical devices such as TAVI.
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OBJECTIVES: Expert consensus recommends follow-up (FU) for patients with pace-
makers to be performed twice annually, with implantable cardioverter defibrilla-
tors or cardiac resynchronization therapy devices four times annually. Most of the
routinely scheduled calendar based FU in-office visits do not require further action
but contribute to the consumption of limited health care resources. This model
estimates the resource use associated with in-office FU visits in Germany and the
UK (UK).METHODS:Own estimates on the number of FU visits were combined with
previously published data on frequency and distance of private and public trans-
port. Recently published data on healthcare personnel resource use were consid-
ered to model hospital resource use. Data were modeled until 2015. RESULTS: If
service providers continue the current service model of routine calendar based
in-office visits for CIED patients, about 2.23 mio visits will be needed in Germany,
and 836’000 in the UK in 2015. These visits would consume approximately 1.11 mio
hours of time in consulting rooms in Germany, and 418,000 hours in the UK. More
than 87,000 ambulance transports in Germany and 33,000 in the UK will be required
for patients attending FU visits. Patients able to use their own transport will drive
about 287 mio kilometers in Germany and 28 mio kilometers in the UK. Workload
for physicians, nurses and technicians will reach 1.1 mio hours in Germany, and
406,000 hours in the UK, most of them being provided by physicians. These esti-
mates do not yet include unscheduled and emergency services for CIED patients.
CONCLUSIONS: The increasing number of in-office FU visits will continue to place
a heavy burden on primarily cardiology service providers but also on patients.
Technologies such as BIOTRONIK’s Home Monitoring can assist hospitals in han-
dling the increasing service demand, free patients from unnecessary travel burden,
and ensure adherence to FU.
PMD72
MAMMA CARCINOMA – DATA ANALYSES AND CLASSIFICATION OF
TREATMENT IN AUSTRIA
Schiller-frühwirth I1, Zauner G2, Einzinger P3, Breitenecker F4
1Main Association of Austrian Social Security Institutions, Vienna, Austria, 2Dwh Simulation
Services, Vienna, Austria, 3Dwh Simulation Services, Vienna, Vienna, Austria, 4Vienna
University of Technology, Vienna, Austria
OBJECTIVES: Cost of illness analysis of breast cancer in Austria using mainly Aus-
trian billing data from intramural and extramural medical treatment based on data
from 2006/07 for treatment and degree of severity evaluation. Regarding this proj-
ect a detailed treatment course classification has to be realized to evaluate the
costs and patient ways in Austrian health system. METHODS: Main strategy of the
project is the combination of data samples detected by Austrian cancer registry and
billing data of intramural and extramural single person datasets in combination
with intake data of medication for each patient. By combining the recorded data
from national statistics, including TNM-classification of each new breast cancer
case, and the ICD10-diagnoses, as well as medical individual services, results in
classification of breast carcinoma on single person level are achieved. For separa-
tion of drug treatment concerning chronical diseases versus cancer indicated drug
administration, the half year time span before the first mamma carcinoma detec-
tion and the year afterwards is analyzed separately. Special medication groups are
assessed in detail and inclusion/exclusion – criteria for costs and treatment are
defined. RESULTS: Based on this identification an alternative subsumption of new
detected carcinoma in six groups (hormone receptor positive, Her 2 positive, hor-
mone receptor positive and Her 2 positive, triple negative, metastasizing mamma
carcinoma, early stage mamma carcinoma without chemo therapy in course of
treatment) is defined.CONCLUSIONS:This classification leads to better insights for
cost evaluation representing the state of the art in Austria. This strategy also leads
to better overall reliability because the margin of uncertainty of the parameters can
be reduced significantly.
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OBJECTIVES: To review reports of anaphylactoid reactions from gadolinium prod-
ucts (GPs) and iodinated contrast media (ICMs) and to compare events, outcomes,
and signals associated with different GPs. METHODS: We reviewed ARs in the FDA
Adverse Event Reporting System (AERS) and compared reports for GPs and ICMs.
We searched FDA-AERS using all reaction terms for ARs linked with GPs and, sep-
arately, ICMs. We compared demographics, outcomes, and types of reactions be-
tween GPs and ICMs. We compared signal detection results for each GP using
proportional reporting ratios (PRRs) and 95% confidence intervals (CI). RESULTS:
Through March 2010, there were 494 and 2,533 reports for GPs and ICMs, respec-
tively. The data are not confluent since ICM usage preceded GP usage (first ICM
event date: 1943, received by FDA: 1969; first GP event date: 1969, received by FDA
1998). Mean ages ( standard deviation) were 49.118.0, and 5718.5, and % male/
female were 38%/59% and 40%/43% for GPs and ICMs, respectively. The ARs for GPs
and ICMs were serious in 91.7%/97.5% and fatal in 7.5%/13.9%, respectively. Propor-
tions of reports and PRRs (CI) for linear GPs were: gadopentetate dimeglumine 
45.3%, 5.03 (4.34-5.71), gadobenate dimeglumine 25.9%, 11.41 (9.67-13.46). For the
other linear GPs, gadodiamide was reported in 7.9% and gadoversetamide in 0.1%,
but the number of cases of use of the agents alone were too small to determine PRR.
Gadoteridol, a cyclic GP, was reported in 18.2% of cases with a PRR of 5.27 (4.30-6.45).
Overall, PRRs were indicative of safety signals for both GPs and ICMs, 5.9, (5.4-6.4),
7.4 (CI: 7.1-7.7), respectively. CONCLUSIONS: FDA-AERS data indicate that GP-as-
sociated ARs generate a safety signal comparable to ICMs. Although over 80% of
GP-associated ARs were with linear GPs, there was a significant safety signal for
one macrocyclic structure GP as well as two linear structure GPs.
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OBJECTIVES: The use of home dialysis modalities such as peritoneal dialysis and
home haemodialysis varies across Europe and North America from today 5% in
Germany to 28% in Denmark. These differences have often been attributed to re-
imbursement and renal care organization factors. This analysis was undertaken to
quantify the strength of association of potential factors influencing usage of home
dialysis modalities with the intent to later facilitate evidence based policy choices.
METHODS: A 4-pillar framework including 8 different factors (home target, reim-
bursement level, payment flow, pre-dialysis education, assisted dialysis, home
guideline/policy, incentives for home, monitoring/planning tool) was postulated to
explain the variation in home dialysis usage across countries. A semi-quantitative
scoring algorithm was developed and used to rate the renal care organization of 12
European countries, Canada, and the USA based on publicly available information.
A regression analysis was used to explore the relationship between the score and
the use of home dialysis modalities as retrieved from the latest available renal
registry reports. The most significant factors were identified by analysis of
variance. RESULTS: A significant (r20.694; p0.001) correlation was found be-
tween the total score and home dialysis usage. Countries like Denmark and Swe-
den achieving a score of 5 have a 26-28% usage of home modalities. In comparison,
Germany had a score of 2 and 5% of dialysis patients are on home modalities.
Three factors were especially significant: well funded and independent pre-dialysis
education (p0.001), clinical guideline/policy favouring home modalities
(p0.002), and (absence of) provider-driven demand (p0.035). CONCLUSIONS:
The 4-pillar framework appears to be useful to identify gaps in a country renal care
policy and decide on further actions to be taken when intending to increase usage
of home dialysis modalities. Actions to implement/correct pre-dialysis education,
clinical guideline/policy favouring home modalities and (absence of) provider-
driven demand should probably be prioritized.
PMD75
PATIENT SELF-TESTING OF ORAL ANTICOAGULATION THERAPY BY
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OBJECTIVES: to explore the effects of patient self-testing (PST) of oral anticoagula-
tion therapy (OAT) by CoaguChek® XS System compared to standard available care
(laboratory testing) for selected group of patients. METHODS: Health Economy
Model (HECON), using Cost-Effectiveness Analysis (CEA), complemented by Bud-
get-Impact Analysis (BIA) on public health insurance coverage in Slovakia. We
searched MEDLINE, Cochrane and available grey literature (Industrial Sources and
Expert Opinions) for meta analyses, systematic reviews, economic evaluation stud-
ies and health technology reports on PST of OAT. Outcomes analyzed were feasi-
bility and accuracy of PST, thromboembolic events, hemorrhagic complications
and mortality. Real-world data from General Health Insurance, Inc. were used for
costs associated with corresponding diagnoses, complications and management of
patients on OAT, including full cohort of patients (n100, average age of 63 years)
on PST. Markov Model (life time horizon) for OAT patient management was devel-
oped, comparing PST with standard care. Outcomes observed were major throm-
boembolic events, major hemorrhagic complications and mortality. Payer perspec-
tive and direct healthcare costs only, associated with OAT management were
considered in CEA and BIA for diagnosis subgroups. Discount rate of 5% was used
for costs as well as outcomes. Sensitivity analysis for major complications was
performed. RESULTS: CEA for PST vs. standard care associated with OAT shows
that intervention is cost-effective (dominant) for all diagnosis subgroups. Net costs
(BIA) associated with PST for expanding the existing cohort of patients 10 times
(n1000) are 1.596 mil. € in Year 1 (up to 3.579 € in Year 5). CONCLUSIONS: PST of
OAT is considered cost-effective in terms of International Normalized Ratio (INR)
regulation and safer in terms of complications. Moreover, analysis of selected sub-
populations (mitral and/or aortic mechanical heart valve implantation, aortic
and/or other aneurysm and congenital cardiovascular malformations) shows that
PST brings the most significant cost-savings especially for those OAT patient seg-
ments.
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ARE HEALTH TECHNOLOGY ASSESSMENTS OF MEDICAL DEVICES CATCHING
UP WITH PHARMACEUTICALS?
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OBJECTIVES: To evaluate how HTA is applied to medical devices (MD) and to assess
whether established HTA agencies have similar influences over MD coverage and
reimbursement decisions compared to pharmaceuticals. METHODS: Manual
search of 69 HTA agencies’ websites was conducted to determine whether they
undertake MD HTAs. Of the agencies that reported MD assessments, we evaluated
the HTA process in respect to methodological approaches and influence on market
access decisions. RESULTS:The majority (49 out of 69) of HTA agencies conduct MD
assessments and make these appraisals publically available. Thirty-five of these
agencies provide reimbursement advice in their reports. In most cases recommen-
dations serve as non-mandatory guidance, aimed at helping local and national
stakeholders make informed decisions about the use of the device within their
health care system. Despite widespread use of MD evaluations, the number of
completed reviews is relatively low. Sixty percent of the agencies that performed
MD HTAs (29 out of 49) applied similar methodologies to both MD and drug
assessments. CONCLUSIONS: While the majority of HTA agencies are adding MD
assessments to their work plans, procedural pathways are not as transparent and
robust as those for pharmaceuticals. Combined with the low output of publications
this currently leads to limited application of MD HTAs to market access decisions.
However, a new system is emerging which recognizes the unique features of MD
and the distinctive level of evidence needed for regulatory approval. In future we
anticipate that market access of medical devices will be centralized under the
umbrella of existing HTA agencies. Thus, following the example of NICE, HAS and
CVZ which have established one national HTA process, with independent path-
ways within their agencies for both drug and MDs.
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OBJECTIVES: The objectives of this paper are to present the current status of HTA
in the field of radiology and describe the role played by Chilean Health System
governmental institutions and private agents in the decision-making process in
order to allocate resources for the incorporation of new technology. METHODS: A
bibliographical review was made based on the opinions of local experts, and a
review of the available local literature. RESULTS: The decision-making process of
acquiring a new technology in radiology is different depending on whether the
provider is public or private. For public providers, first, the hospital solicits to
include the purchase of the equipment in the budget for the year immediately
following. Then, the decision is taken by the Ministry of Health (MINSAL). It is a
centralized decision, but not subdue to a formal economic assessment. For private
providers, the decision usually comes from the clinical need. An economic assess-
ment for viability is carried out, expected demand and budgeted costs of examina-
tion are calculated in order to calculate the payback time on investment and finally
decision to purchase is made. CONCLUSIONS: Data on health economics are in-
creasingly important to the Chilean health authorities, even though, they are not
considered essential to make decisions. At present, there is more awareness of the
importance of implementing methods of analysis. Therefore, it is advisable to
continue providing such information. On the whole, the decision to purchase a new
technology in radiology depends on whether the provider is public or private. It
does not involve variables derived from complex economic or structured studies,
but depends on the need of the equipment and market availability.
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OBJECTIVES: Skull Deformaty (SD) is a flattening of the head as a result of pressure
on the malleable skull in infants in the first months of life. Presently, a RCT is
conducted to compare the effect of an orthotic helmet to the natural recovery of
skull shape in the first three years of life. Burden of treatment is considerable; the
helmet has to be worn 23 hours a day for at least 6 months. Possible harms include
acceptation problems, pressure wounds and severe skin rash or eczema. The
harms of treatment are perceived as an important reason for low adherence to and
parental refusal of helmet treatment. The objective of this study is to estimate the
risk-benefit trade-off in SD management in pediatric physiotherapists. METHODS:
A discrete choice experiment was performed with the most important attributes of
SD management. A total of 267 pediatric physiotherapists stated their preference
for treatment of a 5 month old child with SD. A three scenario design was chosen
Each scenario was characterized by its effect, its burden and the harms of treat-
ment. Logistical regression analysis was performed to analyze the results of the
discrete choice experiment. RESULTS: Not surprisingly, child physiotherapists’
ideal treatment has a high probability of timely success with low burden and min-
imal harms. At present, most attributes indicate a strong preference for awaiting
natural recovery. Risk benefit assessment favoring the helmet will only be attained
if the helmet can show highly significant clinical benefit. CONCLUSIONS: This
study shows that risk benefit analysis can give early indications on the potential of
a treatment, by estimating the effectiveness at which the treatment becomes more
favorable than its comparator. Whether the risk-benefit analysis will be in favor of
helmet treatment in the case of SD, is questionable, as earlier studies have not
demonstrated superiority of the helmet.
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MUCH PRACTICE VARIATION IS THERE?
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OBJECTIVES: There is increasing interest in estimating the health and economic
impact of a new technology in the early phases of its development. However, this
requires knowledge about current care. We examined how non-invasive imaging is
currently used to assess carotid stenosis in patients with a recent TIA or minor
ischemic stroke, as a first step in an early economic evaluation of new imaging
technologies which will be used for the prediction of the risk of plaque rupture.
METHODS: We first examined the current guidelines in the The Netherlands, Eu-
rope and US regarding the use of non-invasive imaging tests (i.e. CT angiography
(CTA), duplex ultrasonography (DUS), MR angiography (MRA)) in the assessment of
carotid stenosis in patients with a TIA or minor ischemic stroke. In addition, semi-
structured interviews were conducted with neurologists in several Dutch hospitals
to determine how patients are actually diagnosed in daily clinical practice.
RESULTS: Current guidelines differ in the use of non-invasive imaging tests in
assessing carotid stenosis in patients with a recent TIA or minor ischemic stroke. In
addition, practice variation is high, since hospitals use different (combinations of)
tests. According to the neurologists, these differences are probably caused by ca-
pacity problems, degree of expertise in performing certain tests and lack of evi-
dence regarding effectiveness and cost-effectiveness of the imaging tests in assess-
ing carotid stenosis. CONCLUSIONS: The observed practice variation is high, and
has implications for assessing the health and economic impact of the new tech-
nology, since estimating impact requires comparison with current care. The choice
of just one comparator representing current care is therefore meaningless, since
choice of comparator may strongly affect the estimated health and economic im-
pact of the new technology. The final impact of a new technology will be hospital-
dependent, and therefore multiple comparisons and scenario analyses are needed.
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SURGICAL COHORTS USING A RETROSPECTIVE NATIONWIDE PATIENT
DATABASE
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OBJECTIVES: Several observational studies have examined the epidemiological
and social characteristics of patients undergoing hernia surgery, but conclusions
drawn from these studies are generally limited due to the small sample population.
Here we describe patient demographics of hernia repair patients and surgical ex-
penditure using a population-based approach with a retrospective nationwide
database. METHODS: Premier Inc has established one of the largest hospital data-
bases worldwide. It collects patient data from around 500 hospitals in the US.
Hernia surgery was stratified by inpatient or outpatient treatment, hernia repair
surgery type (inguinal, incisional or umbilical), surgical procedure (laparoscopic or
open), and the type of mesh used (flat, tissue-separating or device). Patient demo-
graphics were recorded and are presented for every cohort of patients. Surgical
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